Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03408561
Recruitment Status : Withdrawn (No accrual)
First Posted : January 24, 2018
Last Update Posted : September 17, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Southern California

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This pilot clinical trial studies how well social media listening works in improving clinical trial recruitment in patients with cancer. Social media listening and recruitment on Twitter may enhance enrollment for cancer-related clinical trials.

Condition or disease Intervention/treatment Phase
Breast Carcinoma Colon Carcinoma Kidney Carcinoma Lymphoma Non-Small Cell Lung Carcinoma Prostate Carcinoma Other: Internet-Based Intervention Other: Survey Administration Not Applicable

Detailed Description:

PRIMARY OBJECTIVES:

I. Examine the feasibility (acceptance among University of Southern California [USC] Norris study team members and Twitter users in Los Angeles [LA] county) of targeted social media listening (SML) via Twitter as a tool for enhancing recruitment to cancer trials.

II. Gain preliminary data on the impact (i.e., numbers recruited versus projected accrual compared to historic recruitment) of targeted social media listening (SML) as a tool for enhancing recruitment to cancer trials among Twitter users in LA county.

III. Estimate the effect size of the number of people enrolled associated with the use of targeted social media listening (SML) via Twitter as a tool for enhancing recruitment to cancer trials.

OUTLINE:

Patients who mention specific cancer disease keywords and/or hashtags are identified and receive a message via Twitter. Patients are then contacted for recruitment into a clinical trial.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: The Use of Social Media Listening for Targeted Recruitment of Twitter Users in LA County in Cancer Trials Compared to Historic Recruitment Data: A Mixed-Methods Study
Actual Study Start Date : November 8, 2017
Estimated Primary Completion Date : December 31, 2018
Estimated Study Completion Date : December 31, 2018

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Health Services Research (message via Twitter)
Patients who mention specific cancer disease keywords and/or hashtags are identified and receive a message via Twitter. Patients are then contacted for recruitment into a clinical trial.
 Other: Internet-Based Intervention
Receive message via Twitter

Other: Survey Administration
Ancillary studies


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. User acceptance and satisfaction with social media (SM) as a recruitment method [ Time Frame: Up to 14 months ]
    A questionnaire will be used assess the acceptance of and satisfaction with SM recruitment method among University of Southern California (USC) Norris study team members and Twitter users in Los Angeles (LA) county.

  2. Accrual rate [ Time Frame: Up to 14 months ]
    To be determined by comparing monthly actual versus (vs.) projected rate of recruitment for the trial disease groups (i.e., non-small cell lung cancer, colon cancer, breast cancer, prostate cancer, kidney cancer, lymphoma) using generalized estimating equations, accounting for intra-disease random effects and trends across the 12 months (9 months exposure per trial). These results will then be put into context of the historic recruitment for these diseases at the center.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • TRIAL INCLUSION:
  • Focus on one of the following disease categories: non-small cell lung cancer, colon cancer, breast cancer, prostate cancer, kidney cancer, lymphoma
  • Be a phase 1 trial in expansion, phase 2, or 3
  • Be interventional trials
  • Recruit in English
  • Be Institutional Review Board (IRB)-approved and open to accrual at USC Norris
  • Recruit for at least 9 months at the point of enrollment
  • Set monthly accrual target >= 1/ and annual accrual target >= 12
  • PATIENT INCLUSION:
  • Will include all prospective trial participants in this study that come from Twitter in response of our SM recruitment interventions, provided they meet the specific trial's eligibility criteria

Exclusion Criteria:

  • TRIAL EXCLUSION:
  • Phase 1 trials in dose escalation
  • PATIENT EXCLUSION:
  • Persons who do not meet the eligibility criteria of any of the trials open to accrual will be excluded from participation, and persons who may be eligible (e.g., disease/histology, stage, prior treatment) but do not meet additional trial-specific requirements such as insurance or allergy to drug)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03408561


Locations
Layout table for location information
United States, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Sponsors and Collaborators
University of Southern California
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Thomas Buchanan, MD University of Southern California
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: University of Southern California
ClinicalTrials.gov Identifier: NCT03408561    
Other Study ID Numbers: 0S-17-7
NCI-2017-02145 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
0S-17-7 ( Other Identifier: USC / Norris Comprehensive Cancer Center )
P30CA014089 ( U.S. NIH Grant/Contract )
First Posted: January 24, 2018    Key Record Dates
Last Update Posted: September 17, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Breast Neoplasms
Carcinoma, Non-Small-Cell Lung
Prostatic Neoplasms
Carcinoma, Renal Cell
Kidney Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Lung Neoplasms
Respiratory Tract Neoplasms
 Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Prostatic Diseases
Adenocarcinoma
Urologic Neoplasms
Kidney Diseases
Urologic Diseases